SFI
PHAT icon

Susquehanna Fundamental Investments’s Phathom Pharmaceuticals PHAT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,473
Closed -$190K – 650
2025
Q4 		$190K Hold
11,473
– – 0.01% 516
2025
Q3 		$135K Hold
11,473
– – 0.01% 529
2025
Q2 		$110K Hold
11,473
– – ﹤0.01% 693
2025
Q1 		$71.9K Buy
+11,473
New +$69.7K ﹤0.01% 1033

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Susquehanna Fundamental Investments's PHAT Position: Q1 2026 in Review

Susquehanna Fundamental Investments sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 11,473 shares — an estimated $190K sold.

Susquehanna Fundamental Investments first reported a position in PHAT in Q1 2025 and held it in 4 quarters. The position peaked at $190K in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Susquehanna Fundamental Investments reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 11,473 Phathom Pharmaceuticals shares in Q1 2026, an estimated $190K.
  • Susquehanna Fundamental Investments first reported a position in Phathom Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Phathom Pharmaceuticals position peaked at $190K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2026, filed 15 May 2026.